Fig. 2.

bDMARD-dependent proportion of herpes zoster events in rheumatoid arthritis patients. Periods, including 12–24, 24–36, 36–48, and 48–60 months, were divided by 4 for the normalization of event rates to 3-month periods. Each dot is located in the middle of the month, which represents between-period event rates. The index date refers to the initial date of first-line bDMARD treatment. Patients with censored follow-up investigation were excluded from the calculation of the corresponding event rate